Noam Blei

Partner

Adv. Noam Blei is a partner in S. Horowitz’s Intellectual Property Practice Group, specializing in complex contentious intellectual property matters, with a particular emphasis on patent litigation.

Drawing on his extensive experience, Noam advises and represents prominent multinational and domestic companies on their most challenging intellectual property matters. He serves clients across the pharmaceutical, medical technology, agri-tech, and food sectors, while also representing innovative technology companies, emerging startups, and leading academic institutions and their technology transfer companies. Combining thorough legal analysis with practical business solutions, Noam enables clients to navigate complex intellectual property challenges while advancing their commercial objectives.

Noam’s practice covers the full spectrum of intellectual property law, from patents and trademarks to trade secrets and design rights. He focuses on complex patent-related matters, guiding clients through sophisticated questions of infringement, validity, ownership, and inventorship. With significant experience in high-stakes patent disputes of significant legal and scientific complexity, Noam regularly represents clients in opposition and revocation proceedings before the Israel Patent Office and in enforcement actions before the courts, with particular experience in major pharmaceutical patent litigation involving blockbuster drugs.

 

“Noam Blei has an excellent ability to explain complex patent issues to businesspeople. Noam always knows exactly what he is doing, which questions to ask, and which evidence will be of high value in a trial. His work is thorough, and he leaves no stone unturned to make a winning case".

Noam also gained extensive expertise in advising and representing clients in disputes relating to employee inventions (also known as “service inventions”), including before the Compensation and Royalties Committee and the High Court of Justice. Notably, Noam was involved in several precedent-setting cases in this area of law.

Core Capabilities

  • Intellectual Property Disputes
  • Patent Litigation & Enforcement
  • Service Invention Disputes
  • Freedom to Operate
  • Pharmaceuticals & Biotech
  • Trade Secrets and Confidential Information
  • Tech Transfer

Notable Representations

  • Successfully represented Teva in a complex patent opposition against Merck regarding JANUVIA, a diabetes blockbuster drug
  • Successfully defended Teva against Novartis’s motion for preliminary injunction concerning GILENYA, a multiple sclerosis blockbuster drug
  • Secured precedent-setting victories in service invention compensation disputes, in which he successfully defended clients such as Iscar Cutting Tools and Teva
  • Advised leading academic institutions and their technology transfer companies, such as Tel-Aviv University and Ramot, Yissum (the tech-transfer branch of the Hebrew University), the Open University and Bezalel Academy of Arts and Design
  • Advises various technology-based companies and startups on critical IP matters

recognition

Education

  • LL.B., cum laude and Dean’s List, Tel Aviv University, 2002

Admission

  • Israel Bar (2004)

Contact

Expertise

Languages

Hebrew, English, French

News & Insights:

By Noam Blei

Access our legal insights, thought leadership and expert analysis

Articles

Novartis’ PI Motion re Gilenya® Denied: Generic Entry Does Not Necessarily Cause “Catastrophic Damages” to the Brand

The Israeli Tax Authority has issued groundbreaking guidance on SAFE instruments, providing much-needed clarity for venture capital investments.

Position Application

Subscribe

Get the latest updates straight to your inbox

SHARE

Facebook
LinkedIn
WhatsApp
Email
Print